financetom
Business
financetom
/
Business
/
Owlet's Q2 revenue beats analyst estimates, announces CEO transition
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Owlet's Q2 revenue beats analyst estimates, announces CEO transition
Aug 7, 2025 2:21 PM

Overview

* Owlet Q2 revenue grows 25.9% yr/yr, beating analyst expectations, per LSEG data

* Co announces CEO transition with Jonathan Harris succeeding Kurt Workman

Outlook

* Owlet expects 2025 revenue between $97 mln and $100 mln

* Company anticipates 2025 gross margins of 46% to 50%

Result Drivers

* PRODUCT SALES - Higher sales of Dream Sock and Dream Duo products drove revenue growth

* GROSS MARGIN IMPROVEMENT - Gross margin increased due to favorable product mix and lower costs

* SUBSCRIPTION GROWTH - Owlet360 subscription surpassed 66,000 paying subscribers, boosting recurring revenue

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $26.10 $22.20

Revenue mln mln (4

Analysts

)

Q2 Beat -$0.05 -$0.22

Adjusted (3

EPS Analysts

)

Q2 EPS -$2.37

Q2 Gross 51.3%

Margin

Q2 $15.30

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for Owlet Inc ( OWLT ) is $11.50, about 38.3% above its August 6 closing price of $7.10

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Tesla Reducing Prices of Model Y SUVs
Tesla Reducing Prices of Model Y SUVs
Apr 5, 2024
09:09 AM EDT, 04/05/2024 (MT Newswires) -- Tesla (TSLA) is reducing prices of Model Y SUV as the rear-wheel drive will now cost $41,390, down from $45,990 previously, the company said in a post on X. Performance and long-range Model Y SUV prices will also be slashed by at least $5,000, Bloomberg reported Friday. The company is cutting down prices...
GRAPHIC-US equity funds see first weekly outflow in six weeks
GRAPHIC-US equity funds see first weekly outflow in six weeks
Apr 5, 2024
April 5 (Reuters) - U.S. investors pulled back from equity funds in the week ending April 3, marking an end to a five-week buying streak, prompted by concerns over Federal Reserve's interest rate cuts following recent robust manufacturing and labour market data. According to LSEG data, investors liquidated a net $3.28 billion worth of U.S. equity funds in their first...
GEO Enters Private Exchange Agreements for 6.50% Convertible Senior Notes
GEO Enters Private Exchange Agreements for 6.50% Convertible Senior Notes
Apr 5, 2024
09:16 AM EDT, 04/05/2024 (MT Newswires) -- GEO Group ( GEO ) said Friday it has entered into private exchange agreements with some 6.50% convertible senior noteholders. GEO Corrections Holdings' noteholders will swap $177 million in total principal amount of the outstanding 6.50% notes for an estimated current value of $305 million, the company said. The compensation will include cash...
U.S. FDA allows expanded use of Bristol Myers' cell therapy
U.S. FDA allows expanded use of Bristol Myers' cell therapy
Apr 5, 2024
April 5 (Reuters) - The U.S. Food and drug Administration on Friday allowed use of Bristol-Myers Squibb ( BMY ) and 2seventybio's cell therapy Abecma in less severely affected patients with a type of blood cancer. The health regulator is also reviewing another cancer cell therapy, Carvykti, from Johnson & Johnson ( JNJ ) and its partner Legend Biotech (...
Copyright 2023-2026 - www.financetom.com All Rights Reserved